BeOne Medicines (ONC) Q3 2026 earnings review
BeOne's main cancer drug speeds up, and profit more than doubles
BeOne Medicines, a global cancer drugmaker, reversed a three-quarter slowdown in its main blood-cancer pill while more than doubling operating profit. Revenue rose 34% to $1.89 billion as US sales of Brukinsa sped up to 36% growth, and slower overhead growth lifted operating profit far above what the company's own plan pointed to. Co-founder and chief executive John Oyler raised the full-year profit outlook by $200 million, though by our math the new plan still implies fourth-quarter operating profit dropping by more than a third.
| Revenue | $1.89B +34% from a year ago |
|---|---|
| US Brukinsa sales | $1.0B +36% from a year ago (vs +30.5% in Q2) |
| Operating income | $419M +157% from a year ago |
| Full-year revenue outlook | Raised $250M middle of the range: 30% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because US Brukinsa growth sped up against last year's toughest comparison and the next-generation blood-cancer drug tacabrutideg passed its Phase 2 trial. One caution: although Oyler highlighted newly approved Beqalzi, the company still hides its sales inside a small "other" bucket and pushed the tacabrutideg regulatory filing into mid-2027.
The question now is whether the implied fourth-quarter drop in profit is another cautious forecast or a real jump in trial and launch spending. Either BeOne is repeating its habit of setting an easy bar after three straight raises, or late-stage trials and new launches will absorb $140 million of extra quarterly expense. Fourth-quarter operating expenses will settle it.
🐂 Bull Case
US Brukinsa Growth Speeds Up Again
Brukinsa, BeOne's flagship pill for blood cancers, brings in nearly three-quarters of company revenue. Sales growth in the United States had slowed for three straight quarters, dropping from 47% a year ago to 30.5% last quarter. That slide raised fears that rival treatments were taking patients.
This quarter, US Brukinsa sales reached $1.0 billion, up 36% from a year ago. Global sales of the drug hit $1.4 billion, up 34%, which implies about $400 million outside the US, up 32% by our math. Higher Brukinsa sales across all regions also lifted product gross margin by 4 percentage points, excluding one-offs, to 90%.
Reaccelerating to 36% against last year's toughest comparison argues against near-term share loss in the US. Because one quarter fades a standing concern without settling it, the company still needs to show this pace comes from patient volume rather than temporary distributor buying.
What to watch: the volume and price breakdown for US Brukinsa in the third-quarter filing. Steady patient volume growth above 25% would confirm that competing blood-cancer regimens are not slowing demand.
Operating Profit More Than Doubles on Slower Spending
BeOne has been turning fast drug sales into profit by keeping overhead growth well below revenue growth. Three months ago, the oncology group's full-year outlook pointed to only $425 million to $525 million of operating profit for the entire second half.
The company earned $419 million of operating profit in the third quarter alone, up 157% from $163 million a year ago. Operating margin jumped 10.6 percentage points to 22.2% of revenue. Selling and administrative costs—commercial and office overhead—fell 6.1 percentage points of revenue to 31.4%, while research and development spending dropped 2.1 points to 35.0%.
BeOne raised its full-year operating profit outlook by $200 million, to between $1.2 billion and $1.3 billion. By our math, the middle of that new plan still leaves just $256 million of operating profit for the fourth quarter because it assumes a $140 million jump in quarterly spending.
What to watch: fourth-quarter selling and research expenses against the implied $1.39 billion figure. Landing below that spending level would deliver a fourth straight profit beat.
Next-Generation Pipeline Clears Key Trials
BeOne wants to prove it is more than a single-drug company by advancing new blood and solid-tumor treatments into late-stage testing. In the third quarter, the drugmaker hit several clinical targets across its pipeline and signed a clinical and Asian commercial partnership with Revolution Medicines.
- Tacabrutideg, a protein degrader for blood cancer: Phase 2 trial "met its primary endpoint of overall response rate" in returning leukemia
- Solid-tumor drugs: first patient data shared at the European medical congress for lung-cancer candidates BG-C477 and BGB-58067
- Late-stage starts: Phase 3 ovarian-cancer study begun for BG-C9074, and first patient dosed for RAS inhibitor BG-85738
Clearing the Phase 2 goal for tacabrutideg lowers the clinical risk on BeOne's next blood-cancer franchise. However, the company moved the potential regulatory filing for tacabrutideg to mid-2027, roughly six months later than the second-half 2026 target listed last quarter.
What to watch: detailed patient response data for tacabrutideg and Brukinsa's Phase 3 MANGROVE study at the December hematology meeting. Strong response rates would support the mid-2027 filing timeline.
🐻 Bear Case
New Drug Sales Stay Hidden as Older Ones Shrink
Chief executive John Oyler said results were "anchored by our foundational BTK inhibitor BRUKINSA" and "now joined by our next-generation BCL2 inhibitor BEQALZI". Beqalzi is BeOne's newly approved pill for blood cancer, and Ziihera is its partnered drug for stomach cancer.
Despite that headline billing, BeOne did not report sales for either new launch. By our math, subtracting Brukinsa ($1.4 billion), Tevimbra ($243 million), and Amgen partnered drugs ($167 million) from $1,855 million of total product revenue leaves only about $45 million for all other drugs combined, down from $47 million last quarter. In the same period, the company took a $22 million charge "associated with our decision to discontinue promotion of POBEVCY", an older partnered cancer drug.
This gap matters because Brukinsa still accounts for 74% of total revenue. Until Beqalzi and Ziihera generate enough sales to report on their own, the commercial business remains reliant on a single medicine.
What to watch: the product revenue table in the third-quarter filing for any separate line on Beqalzi. Keeping the drug inside the "other" bucket would show early US commercial uptake remains small.
Borrowing Costs Jump on a $5.9 Billion Cash Pile
Last year BeOne raised $907 million of upfront cash by selling future royalty rights on the partnered lung-cancer drug Imdelltra to Royalty Pharma. Under US accounting rules, that upfront cash sits on the balance sheet as a $913 million liability that accrues interest expense.
In the third quarter, total interest expense more than doubled to $42.4 million from $16.4 million a year ago. That borrowing cost exceeded the $33.7 million of interest income the company earned on its $5.87 billion cash balance. Meanwhile, employee stock compensation of $133 million pushed diluted American Depositary Shares (ADSs, the US-traded stock units) up 2.4% from a year ago to 117.3 million, with no share buybacks.
Paying high imputed interest while holding nearly $3.9 billion in net cash—by our math—drags on net profit, and ongoing stock grants steadily dilute existing holders.
What to watch: any plan to pay down the $1.07 billion of standard bank debt or offset stock dilution in 2027. Keeping both debt and unused cash high would continue the net interest drag.
Risks this quarter didn't answer
Three standing commercial and competitive concerns received no new data in the earnings release because their tables live in the quarterly filing or on the conference call.
- US price rebates and discounts: not in the release; the filing's gross-to-net revenue footnote will show whether rebates rose above last quarter's 23.8% of gross sales.
- Fixed-duration therapy competition: not addressed in the release; the call transcript will show how management views patient treatment duration against fixed-course rivals.
- China biosimilar competition for Xgeva: Amgen partnered sales grew 26% to $167 million, but the release gives no update on 2027 generic entry in China.
👓 Other Themes
US Government Agreement and Fourth-Quarter Tax Benefit
BeOne announced a "voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening the Company’s U.S manufacturing footprint", adding to its New Jersey plant expansion. Separately, sustained profit means the company plans to release accounting reserves on past tax losses and "expects the reversal will occur in the fourth quarter of 2026", creating a large one-time tax benefit.
💲 Other KPIs
Free cash flow—operating cash left after factory spending—rose 34% from a year ago and 9% from last quarter to $474 million. That equals 25.1% of total revenue by our math, as property and equipment purchases fell 27% from a year ago to $35 million.
Sales of Tevimbra, BeOne's immunotherapy for solid tumors, rose 28% from a year ago to $243 million, speeding up from 18% growth last quarter. Sales of medicines licensed from Amgen grew 26% to $167 million, matching last quarter's 25% pace.
Inventories rose 32.8% over the first nine months of 2026 to $808 million, while accounts receivable—money owed by drug distributors—grew 26.3% to $1.09 billion. Both lines tracked the 33% nine-month revenue growth as the company stocked global markets.
🔮 Guidance
Raised. The middle of the full-year range moved up $250 million to $6.95 billion, or 30.1% growth by our math. That is the third raise this year: +$100M, +$300M, and now +$250M. By our math, the new target leaves $1.84 billion for the fourth quarter—up 22.9% from a year ago, but $48 million below third-quarter sales.
Raised. BeOne lifted its full-year operating profit target by $200 million at the middle of the range, following earlier raises of $50 million and $250 million. With $994 million already earned in the first nine months, the middle of the plan leaves $256 million for the fourth quarter by our math, or a 13.9% operating margin against 22.2% in Q3.
Raised. The company increased this target by $200 million after two earlier raises of $50 million and $250 million. By our math, the $1.95 billion middle of the range leaves $420 million for the fourth quarter, down from $612 million in the third quarter.
Raised. BeOne lifted the bottom of its spending range by $100 million, raising the middle by $50 million to $4.95 billion. By our math, that leaves $1.39 billion of research and commercial spending for the fourth quarter, an 11.1% jump from the $1.25 billion spent in the third quarter.
Unchanged. Product gross margin stood at 88% in the third quarter (90% excluding one-offs and the $22 million Pobevcy write-off) and 89.1% across the first nine months by our math, keeping the full-year target on track.
Unchanged. Combined net interest and other items totaled $11.6 million of net expense across the first nine months by our math, leaving room for fourth-quarter interest amortization from the Royalty Pharma agreement.
Unchanged. Weighted-average diluted ADSs reached 117.3 million in the third quarter and 116.3 million across the first nine months, consistent with steady employee stock grants.
❓ Key Questions
Why did the tacabrutideg filing move to mid-2027?
The pivotal Phase 2 trial in returning leukemia met its primary response goal this quarter, but the milestone table shifted the potential regulatory submission from the second half of 2026 to mid-2027. Did regulators ask for longer patient follow-up?
What are the initial sales of Beqalzi and Ziihera?
Oyler highlighted Beqalzi alongside Brukinsa, yet all products outside Brukinsa, Tevimbra, and the Amgen portfolio generated only about $45 million combined by our math. When will BeOne report Beqalzi sales on its own line?
What is in the US Government agreement?
BeOne announced a voluntary agreement with the US Government to expand patient access and strengthen US manufacturing. Does this deal involve pricing commitments for government health programs or new factory spending beyond the $300 million New Jersey expansion?
Did US price rebates keep rising in Q3?
Rebates and returns climbed to 23.8% of gross product sales in the second quarter. What was the gross-to-net deduction rate in the third quarter, and how much of US Brukinsa's 36% growth came from patient volume versus price?